ClinicalTrials.Veeva

Find clinical trials for Eczema in New Haven, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Dermatitis
Atopic Dermatitis
Dyssomnias
Parasomnias
Food Hypersensitivity
Hypersensitivity
Psoriasis

Eczema trials near New Haven, CT, USA:

Locations recently updated

A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy (ADHAND)

The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. Th...

Enrolling
Atopic Hand Eczema
Atopic Dermatitis
Drug: Tralokinumab
Drug: Placebo

Phase 3

LEO Pharma
LEO Pharma

Farmington, Connecticut, United States and 53 other locations

The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) pre...

Active, not recruiting
Atopic Dermatitis
Drug: Lebrikizumab

Phase 3

Lilly
Lilly

Farmington, Connecticut, United States and 41 other locations

The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atop...

Enrolling
Atopic Dermatitis
Drug: Lebrikizumab

Phase 3

Lilly
Lilly

Farmington, Connecticut, United States and 47 other locations

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Placebo for Upadacitinib

Phase 3

AbbVie
AbbVie

Shelton, Connecticut, United States and 179 other locations

The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to <18 years of age with moder...

Enrolling
Eczema
Atopic Dermatitis
Drug: Lebrikizumab
Drug: Placebo

Phase 3

Lilly
Lilly

Farmington, Connecticut, United States and 94 other locations

The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to <18...

Enrolling
Eczema
Atopic Dermatitis
Drug: Topical corticosteroid
Drug: Placebo

Phase 3

Lilly
Lilly

Farmington, Connecticut, United States and 96 other locations

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

Phase 3

Lilly
Lilly

Cromwell, Connecticut, United States and 318 other locations

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Placebo for Upadacitinib

Phase 3

AbbVie
AbbVie

Bridgeport, Connecticut, United States and 195 other locations

The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of ado...

Invitation-only
Atopic Dermatitis
Drug: Placebo
Drug: Upadacitinib

Phase 3

AbbVie
AbbVie

Shelton, Connecticut, United States and 192 other locations

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy treatment.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Drug: Placebo

Phase 3

Amgen
Amgen

Hartsdale, New York, United States and 201 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems